Article Text

PDF

Effects of enzymatic blood defibrination in subcortical arteriosclerotic encephalopathy.
  1. E B Ringelstein,
  2. A Mauckner,
  3. R Schneider,
  4. W Sturm,
  5. W Doering,
  6. S Wolf,
  7. N Maurin,
  8. K Willmes,
  9. M Schlenker,
  10. H Brückmann
  1. Department of Neurology, University Hospital of the RWTH Aachen, Federal Republic of Germany.

    Abstract

    Plasma hyperviscosity is a striking abnormality in patients suffering from subcortical arteriosclerotic encephalopathy (SAE) and is thought to perpetuate the chronic ischaemic demyelinating process of the periventricular white matter. Ancrod, a defibrinating enzyme, was given to 10 patients with SAE in an attempt to reduce plasma fibrinogen, which would thus normalise hyperviscosity. This was paralleled by a significant improvement of the initially abnormal retinal arteriovenous passage time, as well as a significant augmentation of the CO2-induced cerebral vasomotor response. This did not lead, however, to any clinical improvement with respect to performance of neuropsychological tests, recurrences of strokes during a 6 month observation period or improvement of various audiological parameters. The findings indicate that hyperviscosity in patients with SAE is merely an epiphenomenon. A potentially reversible, chronic penumbral state of the brain tissue apparently does not exist in SAE.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.